|
Baseline demographic and clinical characteristics of the pooled study populations |
|||
| Pooled population |
|||
|
|
|||
| Characteristic |
Placebo (n = 209) |
Esomeprazole 20 mg (n = 201) |
Esomeprazole 40 mg (n = 194) |
|
|
|||
| Male/female gender, percentage |
27.3:72.7 |
21.4:78.6 |
24.2: 75.8 |
| Age in years, mean (standard deviation) |
57.1 (13.4) |
54.4 (11.9) |
55.7 (13.6) |
| Type of chronic condition, percentage |
|||
| Rheumatoid arthritis |
24.4 |
18.4 |
20.6 |
| Osteoarthritis |
43.1 |
45.3 |
42.8 |
| Other chronic condition |
32.5 |
36.3 |
36.6 |
| Time since first diagnosis of chronic condition in years, median |
9 |
7 |
9 |
| Helicobacter pylori status (histology), percentagea |
|||
| Negative |
95.7 |
93.0 |
95.9 |
| Positive |
3.3 |
6.5 |
3.1 |
| Unknown |
1.0 |
0.5 |
1.0 |
| NSAID type, percentage |
|||
| Non-selective |
64.1 |
65.7 |
67.0 |
| Selective COX-2 inhibitor |
35.9 |
34.3 |
33.0 |
| Study drug in acute study, percentage |
|||
| Placebo |
24.4 |
29.3 |
32.5 |
| Esomeprazole 20 mg |
43.1 |
32.8 |
36.1 |
| Esomeprazole 40 mg |
32.5 |
37.8 |
31.4 |
|
aH. pylori status derived from the acute studies (NASA1 [Nexium Anti-inflammatory Symptom Amelioration] and SPACE1 [Symptom Prevention by Acid Control with Esomeprazole]). COX-2, cyclo-oxygenase-2; NSAID, non-steroidal anti-inflammatory drug. | |||
Hawkey et al. Arthritis Research & Therapy 2007 9:R17 doi:10.1186/ar2124 |
|||